Scott Bessent Says China To Buy 12 Million Tons Of Soybean This Season After Trump-Xi Meeting: Report

Published : Oct 30, 2025, 06:18 PM IST
https://stocktwits.com/news-articles/markets/equity/scott-bessent-china-12-million-tons-soybean-trump-xi-meeting/cLGFtwVR3xP

Synopsis

Bessent also noted that China has committed to buy at least 25 million tons of soybeans from U.S. farmers in each of the next three years.

Treasury Secretary Scott Bessent on Thursday reportedly stated that China has agreed to purchase 12 million tons of soybeans from the U.S. in the current harvest season.

During an interview with Fox Business, Bessent also noted that China has committed to buy at least 25 million tons of soybeans from U.S. farmers in each of the next three years.

Bessent clarified that China’s purchase commitments for 12 million tons of soybeans are for a period from now to January next year.

The Treasury Secretary’s comments come after President Donald Trump’s meeting with Chinese President Xi Jinping. “I was extremely honored by the fact that President Xi authorized China to begin the purchase of massive amounts of Soybeans, Sorghum, and other Farm products. Our Farmers will be very happy!” said President Trump in a post on Truth Social.

Get updates to this story developing directly on Stocktwits.<

For updates and corrections, email newsroom[at]stocktwits[dot]com.<

PREV

Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.

Recommended Stories

Medline Files For One Of 2025’s Largest IPOs With Potential Valuation Near $55.3B
Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients